Pioneering Innovations in Oncology
Lung Cancer Solutions

close up of two male scientists with safety glasses for header image

High Definition PCR (HDPCR™) NSCLC, Research Use Only (RUO), multiplexed panel provides sample-to-results
in 24 hours for NSCLC variants

ChromaCode’s HDPCR technology enhances your lab’s molecular profiling capabilities by enabling you to perform molecular profiling services in-house without the high cost and complexity of implementing Next Generation Sequencing (NGS). HDPCR pairs proprietary innovations in chemistry and software to deliver the highest level of multiplexing, previously impossible using digital PCR (dPCR).

Key Benefits of

  • 24-hour turnaround from sample to results matches PD-L1 testing turnaround.
  • As low as 15ng input DNA; and 5ng input RNA significantly lower sample requirements than hybrid capture NGS methods.
  • >99% coverage of NCCN* guideline directed clinically relevant variants.**
  • 99% concordance with next generation sequencing (NGS).
x-rays of a human rib cage

Sample to Result Workflow

Sample To Result Workflow​ image, from FFPE through Report Generation in ChromaCode cloud

Clinically Relevant Biomarkers per NCCN*
in the HDPCR NSCLC Panel

BiomarkerMarker Type
ALK FusionsRNA Fusion
EGFR Exon 19Deletion
EGFR Exon 20Insertion
ERBB2 (HER2) Exon 20Duplication & Insertion
MET exon 14 skippingSNVs and Indels
NTRK Fusions 1/2/3RNA Fusion
RET FusionsRNA Fusion
ROS1 FusionsRNA Fusion

Main Features of the

  • Multiple analytes in a single assay – single nucleotide variants (SNV), insertions and deletions (indels) and fusions.
  • Compatible with multiple sample types – FFPE (surgical resections, core needle biopsies and fine needle aspirates).
  • Eliminates sequential single gene testing.
  • Automated interpretation eliminates the need for manual data inspection – the ChromaCode Cloud provides cloud-based analyses that are streamlined and scalable to rapidly generate a results report, no hardware or software install required.

“MedGenome Labs remains committed to introducing innovative omics-based technologies for oncology diagnostics. We are delighted to partner with ChromaCode to bring this groundbreaking technology for pharmaceutical and diagnostic applications to India and the Middle East. We value the exceptional quality of the technology and rapid turnaround time and the global vision of ChromaCode, and we believe this alliance will be instrumental in our efforts to deliver accessible and high-quality healthcare.”

Dr. Vedam Ramprasad, Ph.D.,

CEO MedGenome, India

Competitive Advantages: 24-hour Turnaround Time With Low Input Material

Target TypeChromaCodeAmplicon-basedHybrid Capture
Clinically Relevant Biomarkers per NCCN*YesYesYes
Minimum Sample Requirements20% Tumor Content
5-15ng RNA/DNA
No Tumor Content 
5-10ng DNA
>10 Slides, 20% Tumor Content 
>50ng DNA****
Sample TypesBiopsy, FNA, ResectionBiopsy, FNA, ResectionBiopsy, FNA, Resection
Performance>99% concordance with NGSN/AN/A
Turnaround Time24 hours
3 touchpoints
4 days
6 touchpoints
4 days
6 touchpoints
Throughput (samples per run)5-85-85-8
Interpretation ComplexityNoneHighHigh

*National Comprehensive Cancer Network

**Tate, J. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res 47, 941–947 (2019)

***Depending on manual or automated extraction method used

****Based on FoundationOne®CDx

† For newly diagnosed NSCLC patients